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Abstract
Accumulation of tissue factor (TF) within cells leads to cellular apoptosis mediated through p38 and p53 pathways. In this 
study, the involvement of Src1 in the induction of TF-mediated cell apoptosis, and the mechanisms of Src1 activation were 
investigated. Human coronary artery endothelial cell (HCAEC) were transfected with plasmids to express the wild-type TF 
 (TFWt-tGFP), or a mutant (Ser253 → Ala) which is incapable of being released from cells  (TFAla253-tGFP). The cells were 
then activated with PAR2-agonist peptide (SLIGKV-NH) and the phosphorylation of Src and Rac, and also the kinase activity 
of Src were assessed. Transfected cells were also pre-incubated with pp60c Src inhibitor, FAK inhibitor-14, or a blocking 
anti-β1-integrin antibody prior to activation and the phosphorylation of p38 as well as cellular apoptosis was examined. 
Finally, cells were co-transfected with the plasmids, together with a Src1-specific siRNA, activated as above and the cel-
lular apoptosis measured. Activation of PAR2 lead to the phosphorylation of Src1 and Rac1 proteins at 60 min regardless 
of TF expression. Moreover, Src phosphorylation and kinase activity was prolonged up to 100 min in the presence of TF, 
with a significantly higher magnitude when the non-releasable  TFAla253-tGFP was expressed in HCAEC. Inhibition of Src 
with pp60c, or suppression of Src1 expression in cells, reduced p38 phosphorylation and prevented cellular apoptosis. In 
contrast, inhibition of FAK had no significant influence on Src kinase activity or cellular apoptosis. Finally, pre-incubation 
of cells with an inhibitory anti-β1-integrin antibody reduced both Src1 activation and cellular apoptosis. Our data show for 
the first time that the over-activation of Src1 is a mediator of TF-induced cellular apoptosis in endothelial cells through a 
mechanism that is dependent on its interaction with β1-integrin.
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Introduction
The accumulation of TF within the endothelial cells has 
been reported to contribute to the progression of chronic 
pathological disorders including cardiovascular disease 
[1–4] and cancer [4–7]. This occurs in addition to the pro-
coagulant property of TF and is associated with the ability 
to regulate cellular processes such as migration and prolif-
eration [8–14]. Furthermore, TF is capable of inducing cel-
lular apoptosis through intracellular signalling mechanisms 
[15–17]. Recently, we reported that the accumulation of TF 
within endothelial cells, either through increased retention, 
or by acquisition of TF can promote cellular apoptosis [18, 
19] through mechanisms mediated by p38 mitogen-activated 
protein kinases (MAPKs) [18]. TF-VIIa complex is capa-
ble of activating protease activated receptor (PAR)-2 which 
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results in cellular signalling directly [11–14]. The formation 
of TF-fVIIa-PAR2 complex has also been shown to induce 
cellular signalling leading to gene expression and influ-
ences cellular proliferation, migration and angiogenesis [20, 
21]. In addition, the interaction of TF with β1-integrin has 
recently been suggested to stimulate pro-angiogenic factors 
and to activate various signalling molecules including focal 
adhesion kinase (FAK) and p38 [10, 22–24].
p38 MAPK is a serine/threonine kinase that is activated 
by the phosphorylation of Thr180 and Tyr182 residues in 
response to different stress signals [25] and can promote cell 
apoptosis [26]. Upstream activators of p38 include Src1 [27, 
28] and Rac1 [29, 30]. Src1 is also a component of the focal 
adhesion complex [31]. The activation of PAR2 has been 
shown to result in the phosphorylation of p38 [32]. Moreo-
ver, studies have reported that β1-integrin has the ability to 
induce FAK auto-phosphorylation at Tyr397, which in turn 
binds to the SH2 domain of Src1 protein [33, 34]. As a result 
of Src1-FAK complex formation, the intra-molecular inter-
action between the SH2 domain and the phospho-Tyr527 
in the c-terminal of Src1 is disrupted [35]. The removal of 
the negative regulatory c-terminal creates an active con-
formation resulting in increased catalytic activity of Src1 
[36] and occurs through the exposure of the activation loop 
which allows the phosphorylation of Src1 at Tyr416 [37, 38]. 
Rac1 also influences gene transcription through a number of 
signalling pathways including the c-Jun N-terminal kinase 
(JNK) and p38 MAPK pathway [39, 40]. Rac1 is activated 
by the phosphorylation of Ser71 [41]. In addition, previous 
studies have shown the cross-talk between Src1 and Rac1 
[42, 43] resulting in indirect activation of downstream sig-
nalling pathways.
Both Src1 and Rac1 have been shown to be activated fol-
lowing the engagement of fVIIa and TF [44, 45]. Therefore, 
it is possible that Src1 and/or Rac1 may be capable of relay-
ing the signal initiated by TF, and responsible for the activa-
tion of p38 leading to cellular apoptosis [18]. In this study, 
a previously used model for TF accumulation was used to 
identify and further elucidate the TF-induced apoptotic 
pathway. The model relies on the retention of TF, together 
with the activation of PAR2. The study aimed to elucidate 
the molecular mechanisms that mediate TF-signalling at the 
membrane level, resulting in the activation of p38.
Materials and methods
Cell culture, transfection and cellular activation
The pCMV6-Ac-TF-tGFP plasmid DNA (OriGene/Insight 
Biotechnology, Wembley, UK) was used to express wild-
type or a variant form of TF, as previously described 
[46–48]. Preparations of pCMV6-Ac-tGFP (control) and 
pCMV6-Ac-TFAla253-tGFP were described previously [46]. 
Human coronary artery endothelial cells (HCAEC), devoid 
of endogenous TF were cultured in MV media containing 
5% (v/v) foetal calf serum (FCS) and growth supplements 
(PromoCell, Heidelberg, Germany). The initial experiments 
on Src phosphorylation time course were also carried out 
using human dermal blood microvascular cells (HDBEC) 
to ensure consistency between cells. Cells (2 × 105) were 
seeded out into 12-well plates and transfected with 0.5 µg 
of pCMV6-Ac-TFWt-tGFP, pCMV6-Ac-TFAla253-tGFP or 
pCMV6-Ac-tGFP plasmid DNA. Transfection of the cells 
was carried out using TransIT-2020 (Geneflow, Lichfield, 
UK) according to the manufacturer’s instructions. Cells were 
permitted to express the proteins for 48 h and the expression 
of the TF variants was confirmed by flow cytometry [46, 
49]. Prior to experiments, cells were pre-adapted to respec-
tive serum-free media for 1 h and then activated by incu-
bation with PAR2-AP peptide (SLIGKV; 20 µM). In some 
experiments cells were pre-incubated with pp60c Src inhibi-
tor (TSTEPQpYQPGENL; 0-500 µM) or a control peptide 
(TSTEPQWQPGENL) for 1  h, prior to activation with 
PAR2-AP. In other experiments the cells were pre-incubated 
for 2 h with FAK inhibitor-14 (1,2,4,5-benzenetetraamine 
tetrahydrochloride; 100 µM; Sigma Chemical Company 
Ltd, Poole, UK) or pre-incubated for 1 h with an inhibitory 
anti-β1-integrin antibody (AIIB2; 20 µg/ml; Developmen-
tal Studies Hybridoma Bank University of Iowa, Iowa City, 
USA) [21, 50] prior to activation. Finally, HCAEC were 
transfected with a specific set of  SilencerSelect®-siRNA 
(10 pmol; Life Technologies, Paisley, UK) to suppress the 
expression of Src1 concurrently, or transfected with a com-
parable set of  SilencerSelect®-negative control #1 siRNA 
(10 pmol; Life Technologies) for 48 h prior to activation. 
The concentration of siRNA to knock-down Src1 expression 
was optimised by western blot beforehand.
Cell proliferation and apoptosis assays
Cell numbers were determined by staining with crystal vio-
let as previously described [50, 51] and calculated from a 
standard curve. In addition, cellular apoptosis was quantified 
using the TiterTACS™ Colorimetric Apoptosis Detection 
Kit (AMS Biotechnology, Abingdon, UK) according to the 
manufacturer’s instructions and as described before [18, 19]. 
The criteria for endothelial cell apoptosis were evaluated 
according to the published consensus guidelines [52] and the 
apoptosis established as described previously [53].
Analysis of Src, Rac, FAK and p38 phosphorylation 
by western blot
HCAEC (2 × 105) were seeded out in 12-well plates and 
transfected to overexpress the wild-type or mutant form 
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of TF-tGFP, or tGFP. In some experiments, the cells were 
co-transfected with Src1-siRNA or a control siRNA. Cells 
were activated with PAR2-AP (20 µM) and incubated for 
up to 2 h. The cells were then lysed in Laemmeli’s buffer 
containing a protease inhibitor cocktail (Sigma) and equal 
amounts were separated by 12% (w/v) SDS-PAGE. The 
protein bands were transferred onto nitrocellulose mem-
branes and blocked with TBST (10 mM Tris–HCl pH 7.4, 
150 mM NaCl, 0.05% Tween-20). To determine the total 
and phosphorylated Src1, the membranes were probed with 
a polyclonal rabbit anti-human Src1 antibody, diluted 1:3000 
(v/v) in TBST and a rabbit monoclonal anti-human phos-
pho-Tyr416 Src-family antibody (D49G4), diluted 1:4000 
(v/v) in TBST (both from Cell Signalling Technologies/
New England Biolabs, Hitchin, UK). Total and phospho-
Rac1 were detected using a polyclonal rabbit anti-human 
Rac1/2/3 antibody diluted 1:3000 (v/v) in TBST, and a 
polyclonal rabbit anti-human phospho-Ser71-Rac antibody 
diluted 1:3000 (v/v) in TBST (Cell Signalling Technolo-
gies). Total and phosphorylated FAK were detected using 
a polyclonal rabbit anti-human FAK diluted 1:3000 (v/v) 
in TBST, and a monoclonal rabbit anti-human phospho-
Tyr397-FAK (D20B1) diluted 1:3000 (v/v) in TBST, respec-
tively (Cell Signalling Technologies). The membranes were 
then washed with TBST and probed with a goat anti-rabbit 
alkaline phosphatase-conjugated antibody (Santa Cruz Bio-
technology, Heidelberg, Germany) diluted 1:1000 (v/v) and 
incubated for 90 min. The bands were then visualised using 
the Western Blue stabilised alkaline phosphatase-substrate 
(Promega) and recorded. Analysis of the phosphorylation of 
p38 was carried out as above but using a rabbit polyclonal 
anti-human p38 antibody diluted 1:3000 (v/v) in TBST and 
a monoclonal mouse anti-human phospho-Thr180/Tyr182-
p38 MAPK antibody (28B10) diluted 1:3000 (v/v) in TBST 
(Cell Signalling Technologies) and then probed with a goat 
anti-rabbit alkaline phosphatase-conjugated antibody and a 
goat anti-mouse alkaline phosphatase-conjugated antibody 
(Santa Cruz Biotechnology) both diluted 1:2000 (v/v), 
respectively. The bands were then visualised using Western 
Blue substrate as above. All quantifications were normal-
ised against GAPDH which was detected using a polyclonal 
goat anti-GAPDH antibody diluted 1:5000 (v/v) and then 
detected using an alkaline phosphatase-conjugated donkey 
anti-goat-IgG antibody diluted 1:2000 (v/v) obtained from 
Santa Cruz Biotechnology.
Analysis of Src1 kinase activity
The  ProFluor® Src-family kinase assay (Promega Corpora-
tion, Southampton, UK) was used to quantify the Src1 enzy-
matic activity within the cells. The kit measures the tyrosine 
kinase activity of Src1 by its ability to catalyse the phos-
phorylation of a provided substrate molecule (Src-Family 
Kinase rhodamine 110; R110 substrate) the phosphorylation 
of which prevents further digestion with a provided protease. 
The amount of the released fluorescence substrate is there-
fore inversely proportional to the Src kinase activity and 
may be determined from a standard curve prepared using 
provided active Src. Briefly, HCAEC (2 × 105/well) were 
seeded and transfected to express the wild-type TF-tGFP, the 
mutant form of TF  (TFAla253-tGFP), or tGFP as control, and 
incubated for 48 h to permit protein expression. Cells were 
then adapted to low-serum medium MV containing 2% (v/v) 
FCS for 60 min and activated with PAR2-AP (20 μM) for 
a further 90 min. The cells were then lysed in PhosphoSafe 
Extraction Reagent (Sigma) and the Src1 activity measured 
as follows. Cell lysates (5 μl) were placed in separate wells 
in opaque-walled 96-well plates and the kinase peptide sub-
strate solution (20 μl) and ATP solution (25 μl) was added 
to each well and incubated with shaking for exactly 60 min 
at room temperature. The protease solution (25 μl) was then 
added and incubated for a further 60 min at room tempera-
ture and the reaction was then stopped using the provided 
stabiliser solution (25 μl). The fluorescence intensity of 
the released rhodamine was measured at Em 530 nm (Ex 
485 nm), using the absorption of the included AMC at Em 
460 nm (Ex 355 nm), as reference for the initial substrate 
concentration.
Statistical analysis
All data represent the calculated mean values from the 
number of experiments stated in each figure legend ± the 
calculated standard error of the mean. Statistical analysis 
was carried out using the Statistical Package for the Social 
Sciences (SPSS Inc. Chicago, USA). Significance was deter-
mined using one-way ANOVA (analysis of variance) and 
Tukey’s honesty significance test or where appropriate, by 
paired t test.
Results
The presence of TF prolongs Src1 phosphorylation 
but not Rac1 phosphorylation following PAR2 
activation
In the first instance, experiments were carried out to analyse 
the time-course of phosphorylation of Src and Rac and to 
determine the optimal time-point for measuring the activa-
tion of these two proteins. By expressing the TF in tandem 
with tGFP, it was possible to optimise the expression of the 
hybrid protein in the cells, prior to analysis. HCAEC were 
transfected to express  TFWt-tGFP,  TFAla253-tGFP, tGFP or 
use untransfected. All cells were then adapted to serum-
free medium and activated by incubation with PAR2-AP 
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(20 µM). Samples of cells were lysed at intervals up to 
120 min and the phosphorylation of Src and Rac analysed 
by western blot. Activation of PAR2 in all cells resulted in 
a small rise in the phosphorylation of Src (Fig. 1) peaking 
at around 60 min. Moreover, on expression of either form 
of TF, the phosphorylation of Src was prolonged forming 
a second peak at around 100 min post-activation (Fig. 1b, 
c). This prolonging of the Src activation was most promi-
nent on expression of the mutant form  (TFAla253-tGFP) but 
was observable with a lower magnitude on expression of 
the wild type  (TFWt-tGFP) in cells. To ensure consistency 
between various endothelial cell types as reported previously 
[52], the phosphorylation of Src was also examined at 0, 60 
and 100 min in human dermal blood microvascular cells 
(HDBEC) which were transfected to express  TFAla253-tGFP 
(Supplementary Fig. 1). The activation of HDBEC also 
induced an increase in Src phosphorylation which was com-
parable to that obtained with HCAEC, and is consistent with 
previous studies regarding the responses of endothelial cells 
[54].
In contrast, activation of cells expressing tGFP (Fig. 2a), 
 TFAla253-tGFP (Fig. 2b),  TFWt-tGFP or the untransfected 
cells (Supplementary Fig. 2) produced a similar Rac-phos-
phorylation peak at around 60 min.
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Fig. 1  Analysis of Src phosphorylation by western blot. Human coro-
nary artery endothelial cells (2 × 105) were seeded out into 12-well 
plates and transfected with 0.5 µg of a pCMV6-Ac-tGFP, b pCMV6-
Ac-TFAla253-tGFP, c pCMV6-Ac-TF-tGFP plasmids, along with d an 
untransfected set of cells. The cells were incubated for 48 h to per-
mit the expression of the recombinant proteins. Sets of cells were 
activated with PAR2-AP (20 µM) and incubated for up to 120 min. 
The cells were then lysed in Laemmeli’s buffer containing a protease 
inhibitor cocktail and separated by 12% (w/v) SDS-PAGE and trans-
ferred onto nitrocellulose membranes. The membranes were probed 
with a polyclonal rabbit anti-human Src1 antibody, diluted 1:3000 
(v/v) or a rabbit monoclonal anti-human phospho-Tyr416-Src family 
antibody (D49G4), diluted 1:4000 (v/v) in TBST. The membranes 
were then washed and probed with a goat anti-rabbit alkaline phos-
phatase-conjugated antibody diluted 1:1000 (v/v) and then visualised 
using the Western Blue stabilised alkaline phosphatase-substrate and 
recorded. All quantifications were normalised against GAPDH which 
was detected using a polyclonal goat anti-GAPDH antibody diluted 
1:5000 (v/v) and then detected using an alkaline phosphatase-conju-
gated donkey anti-goat-IgG antibody diluted 1:2000 (v/v). The ratios 
of phosphorylated to total Src were calculated using the ImageJ pro-
gram. (n = 6; * = p < 0.05 vs. the untreated samples)
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The presence of TF amplifies Src1 phosphorylation 
and Src kinase activity following PAR2 activation
Following establishing the optimal time-point for the meas-
urement of Src phosphorylation, the magnitude of Src phos-
phorylation and the Src kinase activity in cells was com-
pared in cells transfected with the wild-type and the mutant 
form of TF. Quantitative analysis of Src phosphorylation at 
90 min post-activation with PAR2-AP (20 µM) confirmed 
the phosphorylation of Src at this time-point in the pres-
ence of wild-type TF and was significantly enhanced in 
the cells transfected to express  TFAla253-tGFP (Fig. 3a, b). 
Furthermore, analysis of the Src kinase activity at 90 min, 
mirrored the magnitudes of Src phosphorylation (Fig. 3c). 
Finally, quantification of the rate of cell apoptosis using a 
colourimetric TUNEL assay, indicated a putative association 
between Src activation and the induction of cell apoptosis 
(Fig. 3d).
Src1 is a mediator of TF‑induced p38 
phosphorylation and cellular apoptosis
In order to examine the role of Src in TF induced apopto-
sis HCAEC (2 × 105/well) were seeded in 12-well plates, 
incubated overnight and transfected with TFAla253-tGFP 
plasmid. Following 48  h of incubation, the cells were 
adapted to low-serum medium MV containing 2% (v/v) FCS 
for 60 min. The cells were pre-incubated for 60 min with 
pp60c Src1 inhibitor peptide (TSTEPQpYQPGENL) at a 
range of 0–500 μM, or alternatively with a pseudo-inhibitor 
peptide (TSTEPQWQPGENL; 500 μM) prior to activation 
with PAR2-AP (20 μM). Sets of cells were also treated with 
IL-1β (10 ng/ml) as a positive control and incubated for 
24 h. Inhibition of Src in cells overexpressing  TFAla253-tGFP 
reduced the rate of cell apoptosis post-activation with 
PAR2-AP, in comparison to the samples treated with the 
pseudo-Src inhibitor or devoid of the inhibitor (Fig. 4a). This 
decrease in the rate of cell apoptosis on inclusion of the 
pp60c was dose dependent (Fig. 4b).
To further confirm the role of Src1 specifically, in TF-
mediated apoptosis, HCAEC (2 × 105/well) were co-trans-
fected to express  TFAla253-tGFP together with Src1 siRNA 
or alternatively a control siRNA. The concentrations of 
the siRNA were optimised beforehand (Supplementary 
Fig. 3). The cells were adapted to low-serum medium MV 
containing 2% (v/v) FCS for 1 h prior to activation using 
PAR2-AP (20 μM). For comparison, sets of cells were 
treated with IL-1β (10 ng/ml) or used untreated. Cellular 
apoptosis was measured after 24 h post-activation using a 
colorimetric TUNEL assay. Suppression of Src expression 
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Fig. 2  Analysis of Rac phosphorylation by western blot. Human 
coronary artery endothelial cells (2 × 105) were seeded out into 
12-well plates and transfected with 0.5 µg of a pCMV6-Ac-tGFP or b 
pCMV6-Ac-TFAla253-tGFP (additional samples shown in Supplemen-
tary Fig. 2). The cells were incubated for 48 h to permit the expres-
sion of the recombinant proteins. Sets of cells were then activated 
with PAR2-AP (20 µM) and incubated for up to 120 min. The cells 
were then lysed and separated by 12% (w/v) SDS-PAGE and trans-
ferred onto nitrocellulose membranes. The membranes were probed 
with a polyclonal rabbit anti-human Rac1/2/3 antibody, diluted 
1:3000 (v/v) and a rabbit monoclonal anti-human phospho-Ser71-
Rac1 antibody, diluted 1:3000 (v/v) diluted in TBST. The membranes 
were then washed and probed with a goat anti-rabbit alkaline phos-
phatase-conjugated antibody diluted 1:1000 (v/v) and then visualised 
using the Western Blue stabilised alkaline phosphatase-substrate and 
recorded. All quantifications were normalised against GAPDH which 
was detected using a polyclonal goat anti-GAPDH antibody diluted 
1:5000 (v/v) and then detected using an alkaline phosphatase-conju-
gated donkey anti-goat-IgG antibody diluted 1:2000 (v/v). The ratios 
of phosphorylated to total Rac were calculated using the ImageJ pro-
gram. (n = 6; * = p < 0.05 vs. the untreated samples)
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reduced the rate of apoptosis to levels comparable to 
those of the untransfected/untreated cells (Fig. 4c) while 
co-transfection with the control siRNA did not exert any 
influence on TF-mediated cell apoptosis.
Previously, we showed that TF-mediated cell apoptosis 
involves the activation of p38 MAPK [18]. Therefore an 
attempt was made to decipher any association between TF, 
Src and p38 activation. HCAEC (2 × 105/well) were trans-
fected with  TFAla253-tGFP plasmid and incubated for 48 h. 
The cells were incubated with Src1 inhibitor (0–500 μM) 
for 60 min and then incubated for a further 90 min with 
PAR2-AP (20 μM). The cells were then lysed and analysed 
by western blot using mouse anti-human phospho-p38 and 
rabbit anti-human p38 antibodies. The ratios of phospho-
p38: total p38 were then determined. In agreement with 
the above findings, incubation of cells with pp60c Src1 
inhibitor peptide reduced p38 phosphorylation, following 
the activation of the cells (Fig. 4d, e).
The activation of Src in the presence of TF 
is not dependent on FAK phosphorylation
Recruitment of Src to focal adhesion clusters can result 
in the activation Src by FAK. Therefore, to assess the 
involvement of FAK in Src activation, HCAEC (2 × 105/
well) were cultured in 12-well plates and transfected to 
express  TFWt-tGFP,  TFAla253-tGFP, tGFP or were used 
untransfected and incubated for 48 h to express the pro-
teins. The cells were pre-treated with the FAK inhibitor 
(FAK inhibitor-14; 100 µM) for 2 h. The duration of pre-
incubation with 100 µM of the FAK inhibitor was opti-
mised previously (Supplementary Fig. 4). The cells were 
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Fig. 3  Analysis of Src phosphorylation, kinase activity and induction 
of cell apoptosis. Human coronary artery endothelial cells (2 × 105) 
were seeded out into 12-well plates and transfected with 0.5  µg of 
pCMV6-Ac-tGFP, pCMV6-Ac-TFAla253-tGFP, pCMV6-Ac-TF-tGFP 
plasmids, along with an untransfected set of cells. The cells were 
incubated for 48 h to permit the expression of the recombinant pro-
teins. Sets of cells were then activated with PAR2-AP (20  µM) for 
90  min. a The cells were then lysed and phosphorylated and total 
Src1 examined by western blot, as described before. b The ratios of 
phosphorylated to total Src were calculated using the ImageJ pro-
gram. (n = 4; * = p < 0.05 vs. the untreated samples). c HCAEC 
(2 × 105/well) were transfected as above and incubated for 48  h to 
permit protein expression. Cells were then adapted to low-serum 
medium MV containing 2% (v/v) FCS for 60 min and activated with 
PAR2-AP (20 μM) for a further 90 min. The cells were then lysed in 
PhosphoSafe Extraction Reagent and the Src activity measured using 
the  ProFluor® Src-family kinase assay. The fluorescence intensity of 
the released rhodamine was measured at Em 530  nm (Ex 485  nm), 
using the absorption of the included AMC at Em 460  nm (Ex 
355  nm), as reference for the initial substrate concentration. (n = 5; 
* = p < 0.05 vs. the untreated samples). d HCAEC (2 × 105/well) were 
transfected as above and incubated for 48 h to permit protein expres-
sion. Cells were then adapted to low-serum medium MV containing 
2% (v/v) FCS for 60 min and activated with PAR2-AP (20 μM) for a 
further 90 min. The rate of cellular apoptosis was then quantified at 
20 h, using the TiterTACS™ Colorimetric Apoptosis Detection Kit. 
(n = 4; * = p < 0.05 vs. the untreated samples)
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then activated with PAR2-AP (20 μM) for 90 min and 
compared to non-activated cells by western blot. Analysis 
of phosphorylated and total Src antigens indicated a partial 
reduction in the phosphorylation of Tyr416 within Src, 
upon inclusion of FAK inhibitor-14 (Fig. 5a, b). Further-
more, analysis of the phosphorylation of Tyr397 within 
FAK, confirmed the significant decrease in the FAK acti-
vation (Fig. 5c, d). In contrast, measurement of Src kinase 
activity using the  ProFluor® Src-family kinase assay only 
showed a marginal reduction in the Src kinase activity 
following the inhibition of FAK (Fig. 5e). Importantly, 
the rate of cell apoptosis remained unaltered following 
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Fig. 4  Examination of the involvement of Src1 in TF-mediated induc-
tion of cell apoptosis. Sets of HCAEC (2 × 105/well) were transfected 
with pCMV6-Ac-TFAla253-tGFP and incubated for 48 h to permit pro-
tein expression. a Cells were then adapted to low-serum medium MV 
containing 2% (v/v) FCS for 60  min together with the Src1 inhibi-
tor pp60c Src inhibitor (TSTEPQpYQPGENL; 500  µM) and com-
pared to a pseudo inhibitor (TSTEPQWQPGENL 500 nM). The cells 
were then activated with PAR2-AP (20  μM) for a further 90  min. 
A set of cells was also treated with IL-1β (10  ng/ml) as a positive 
control. The rate of cellular apoptosis was then quantified at 20  h, 
using the TiterTACS™ Colorimetric Apoptosis Detection Kit. (n = 4; 
* = p < 0.05 vs. sample devoid of inhibitor). b Sets of cells were trans-
fected as above and then adapted to low-serum medium MV contain-
ing 2% (v/v) FCS for 60  min together with a range of Src1 inhibi-
tor pp60c (0–500 nM). The cells were then activated with PAR2-AP 
(20 μM) for a further 90 min. The rate of cellular apoptosis was then 
quantified at 20  h, using the TiterTACS™ Colorimetric Apoptosis 
Detection Kit. (n = 4; * = p < 0.05 vs. the sample devoid of inhibitor). 
c Sets of HCAEC (2 × 105/well) were co-transfected with pCMV6-
Ac-TFAla253-tGFP plasmid together with wither a Src1 siRNA, con-
trol siRNA or without any siRNA, and incubated for 48 h. The rate 
of cellular apoptosis was then quantified at 20  h, using the TiterT-
ACS™ Colorimetric Apoptosis Detection Kit. (n = 4; * = p < 0.05 vs. 
sample devoid of siRNA). d HCAEC (2 × 105) were transfected with 
pCMV6-Ac-TFAla253-tGFP plasmid and incubated for 48 h to permit 
the expression of the recombinant protein. The cells were then acti-
vated with PAR2-AP (20 µM) and lysed and the amounts of phospho-
rylated-p38 and total-p38 were examined by western blot and e The 
ratios of phosphorylated to total p38 were calculated using the ImageJ 
program. (n = 4; * = p < 0.05 vs. sample devoid of inhibitor)
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the inhibition of FAK (Fig. 5f). To elucidate the mecha-
nism further, the outcome of PAR2 activation on FAK 
phosphorylation, in cells expressing the various constructs 
was examined. Western blot analysis indicated that PAR2 
activation had no influence on FAK phosphorylation which 
also remained unaltered by the expression of either form 
of TF-tGFP (Fig. 5g, h).
Over‑activation of Src1 by TF is dependent 
on β1‑integrin
Finally, the role of β1-integrin in the activation of Src1, in 
cells overexpressing TF was evaluated. HCAEC (2 × 105/
well) expressing the mutant form of TF  (TFAla253-tGFP), 
wild-type  TFWt-tGFP, a control plasmid (tGFP) as well as 
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an untransfected sample, were incubated with an inhibitory 
anti-β1-integrin antibody (AIIB2; 20 μg/ml) for 60 min 
[22, 50]. The cells were then activated using PAR2-AP 
(20 μM) for a further 90 min. Analyses of Src phospho-
rylation showed that blocking of β1-integrin marginally 
reduced the level of Src1 phosphorylation in cells express-
ing  TFAla253-tGFP (Fig. 6a, b). Moreover in agreement with 
the above, FAK phosphorylation remained unaffected (Sup-
plementary Fig. 5). In contrast, incubation of cells with the 
inhibitory anti-β1-integrin antibody significantly reduced 
Src kinase activity (Fig. 6c). The change in Src kinase activ-
ity was also concurrent with substantial reduction in cellular 
apoptosis (Fig. 6d).
Discussion
The release of TF during injury, trauma and infections has 
been well documented. High levels of circulating TF are also 
detected during chronic pathological conditions including 
cancer, diabetes and cardiovascular disease. Endothelial cells 
have been shown to be capable of acquiring exogenous TF, 
in vitro and in vivo [55, 56]. This accumulation of TF can 
overcome the cellular mechanisms of processing TF and as a 
result, the cells may become overloaded with TF. Abnormal 
levels of TF can induce cellular apoptosis which can give 
rise to endothelial dysfunction during disease conditions. 
Previously, we used a model for the accumulation of TF in 
endothelial cells to examine the mechanism of TF-induced 
cell apoptosis [15, 16]. Using this model we showed that 
the prevention of TF release through alanine-substitution of 
ser253 within its cytoplasmic domain, resulted in the induc-
tion of cell apoptosis through a mechanism involving p38 
MAPK and p53. These in turn resulted in cell cycle arrest 
and the expression of bax [18]. In contrast, the expression 
of wild-type TF which is processed normally by the cells, 
lowered the rate of apoptosis and promoted cell proliferation. 
In this study, we have used this model to examine the signal-
ling mediators in the activation of TF-induced apoptosis, but 
at the membrane-associated level. We have demonstrated 
the prolonged (> 90 min) phosphorylation of Src1 following 
the activation of PAR2, in cells expressing TF, but not in 
cells expressing the control plasmid, or untransfected cells. 
The phosphorylation of Src1 was concurrent with increased 
kinase activity of this protein. Importantly, accumulation 
of  TFAla253-tGFP further augmented this outcome, resulting 
in the over-activation of Src1. In contrast, the activation of 
Rac1 was unaltered by the presence of TF. This over-activa-
tion of Src1 was shown to be responsible for the high level 
of p38 phosphorylation and induction of cells apoptosis, 
since either inclusion of the Src inhibitor (pp60c) or siRNA 
mediated suppression of Src1 abolished the increased rate 
of cell apoptosis. The involvement of Src1 in the promo-
tion of cell differentiation and proliferation has been thor-
oughly explored in the past [57, 58]. However, there are 
also some studies which show that the over-activation of 
Src can have a pro-apoptotic influence on cells [59]. Here, 
we have implicated Src1 as a mediator associating the dis-
ruptions in the cellular processing of TF, with the induction 
of apoptosis. These findings agree with the hypothesis that 
as a factor which appears early at the sight of injury, TF is 
ideally placed to have a dual function in instructing the cells 
to divide, or alternatively become apoptotic. Therefore, TF 
may act as a gauge for the level of injury and to distinguish 
between the severely injured cells and those which may be 
revived.
Previous studies have reported the ability of TF to induce 
cellular signalling through binding with the β1-integrin 
[22–24]. Furthermore, the interaction between FAK and 
Src1 is known to be capable of transmitting cellular signals 
initiated by β1-integrin [60, 61]. Therefore in the second 
part of the study, the possible roles of β1-integrin and FAK 
in TF-induced Src1 over-activation were examined. Chemi-
cal inhibition of FAK phosphorylation at Tyr397 using 
FAK inhibitor-14, reduced the phosphorylation of Tyr416 
within Src1. This is in agreement with previous studies since 
Tyr397 phosphorylation within FAK is essential for the for-
mation of Src1-FAK complex leading to the phosphorylation 
of Tyr416 in Src1. Moreover, it has been reported that the 
influence of β1-integrin on Src1 is mediated through activa-
tion of FAK-Src1 complex [62–64]. The clustering of integ-
rins can promote the auto-phosphorylation of FAK at Tyr397 
which generates a binding target for the SH2 domain within 
Src1 protein [33, 34]. The formation of this complex in turn 
Fig. 5  Examination of the involvement of FAK in TF-mediated 
induction of cell apoptosis. Sets of HCAEC (2 × 105/well) were trans-
fected with pCMV6-Ac-tGFP, pCMV6-Ac-TFAla253-tGFP, pCMV6-
Ac-TF-tGFP plasmids, along with an untransfected set of cells and 
incubated for 48  h to permit protein expression. Cells were then 
adapted to low-serum medium MV containing 2% (v/v) FCS for 
60  min together with FAK inhibitor-14 (100  µM) and compared to 
vehicle control. The cells were then activated with PAR2-AP (20 μM) 
for a further 90 min. a The cells were then lysed and phosphorylated 
and total Src1 examined by western blot, as described before. b The 
ratios of phosphorylated to total Src were calculated using the ImageJ 
program. (n = 4; * = p < 0.05 vs. the untreated samples). c Phospho-
rylation of FAK was also analysed by western blot using specific 
antibodies to Tyr397-phosphorylated and total FAK. d The ratios of 
phosphorylated to total FAK were calculated using the ImageJ pro-
gram. (n = 4; * = p < 0.05 vs. the untreated samples). e Sets of cells 
were treated as above and then lysed in PhosphoSafe Extraction Rea-
gent and the Src kinase activity measured using the  ProFluor® Src-
family kinase assay. (n = 4). f In addition, the rate of cellular apopto-
sis was then quantified at 20 h, using the TiterTACS™ Colorimetric 
Apoptosis Detection Kit. (n = 4). g Sets of HCAEC were transfected 
and adapted to serum-free medium as above. One set of cells were 
then activated with PAR2-AP (20 µM) and the level of FAK phospho-
rylation by western blot. h The ratios of phosphorylated to total FAK 
were calculated using the ImageJ program. (n = 4)
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disrupts the intra-molecular interaction between the SH2 
domain and the regulatory phospho-Tyr527 in the c-terminal 
of Src1 [35]. The removal of this negative regulatory domain 
creates an active conformation through the exposure of the 
activation loop. This in turn results in the phosphorylation 
of Src1 at Tyr416 [37, 38] and increased catalytic activity of 
Src1 [36]. However in our study, only a marginal reduction 
in Src1 kinase activity was detected following the inhibition 
of FAK in cells expressing the mutant or wild-type TF. It has 
recently been suggested that FAK inhibition is not sufficient 
to completely suppress Src1 activity since the lack of Tyr397 
phosphorylation in FAK alone, is not sufficient for prevent-
ing Src1 activation [65]. Consequently, Src1 may exist in a 
state where both Tyr416 and Tyr527 remain phosphorylated 
within this protein [66] and may be activated by mechanisms 
that are independent of FAK [65–68]. Additionally, previ-
ous studies have reported that the α4β1-integrin is capa-
ble of activating Src1 independently of FAK [69] through 
mechanism involving other members of the focal adhesion 
complex such as paxillin and vinculin, which were reported 
as binding proteins of Src1 at SH3 [70]. It has also been 
shown that the over-expression of v-Src in FAK-deficient 
cell lines results in the formation of avascular tumours in 
mice suggesting that Src activity alone, may in fact prevent 
vascularisation [71]. Therefore, FAK-Src signalling appears 
to be essential for the paracrine signalling between tumour 
cells and endothelial cells, which is mediated through the 
induction of VEGF expression in the latter cells [72]. How-
ever in our study, Src appeared to be activated without FAK 
activation. Therefore, the over-activation of Src alone, in 
endothelial cells, in response to TF may be detrimental to 
vascular proliferation.
Blocking of β1-integrin using an inhibitory antibody 
(AIIB2), in cells expressing either form of TF, reduced 
both the phosphorylation of Src1 and the associated kinase 
activity, following PAR2 activation. Further analysis of FAK 
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Fig. 6  Examination of the involvement of β1-integrin in TF-medi-
ated induction of cell apoptosis. Sets of HCAEC (2 × 105/well) were 
transfected with pCMV6-Ac-tGFP, pCMV6-Ac-TFAla253-tGFP, 
pCMV6-Ac-TF-tGFP plasmids, along with an untransfected set 
of cells and incubated for 48  h to permit protein expression. Cells 
were then adapted to low-serum medium MV containing 2% (v/v) 
FCS for 60  min together with a blocking anti-β1-integrin antibody 
(AIIB2; 20 µg/ml) and then were activated with PAR2-AP (20 μM) 
for a further 90 min. a The cells were then lysed and phosphorylated 
and total Src1 examined by western blot, as described before. b The 
ratios of phosphorylated to total Src were calculated using the ImageJ 
program. (n = 4; * = p < 0.05 vs. untreated samples; # = p < 0.05 vs. 
respective control IgG). c Sets of cells were treated as above and then 
lysed in PhosphoSafe Extraction Reagent and the Src kinase activ-
ity measured using the  ProFluor® Src-family kinase assay. (n = 4; 
* = p < 0.05 vs. the untreated samples; # = p < 0.05 vs. respective con-
trol IgG). d Sets of cells were treated as above and the rate of cellular 
apoptosis was quantified at 20 h, using the TiterTACS™ Colorimetric 
Apoptosis Detection Kit. (n = 4; * = p < 0.05 vs. the untreated sam-
ples; # = p < 0.05 vs. respective control IgG)
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phosphorylation using western blot, in cells pre-incubated 
with β1-integrin blocking antibody did not show any reduc-
tion in FAK phosphorylation (Supplementary Fig. 5). How-
ever, this antibody (AIIB2) has been shown to reduce FAK 
phosphorylation at Tyr397 [67], and the underlying mech-
anism is thought to involve the interference with integrin 
clustering. This clustering is also essential for the maximal 
activation of Src1 [68, 69]. Therefore, in agreement with 
the above, Src1 appears to be activated by mechanisms that 
are independent of FAK [65]. As mentioned above, other 
studies have also demonstrated that the α4β1-integrin is 
capable of activating Src1 independently of FAK [70], and 
through mechanisms involving other members of the focal 
adhesion complex. In these mechanisms, the binding Src1 
occurs through SH3 domain [71]. Therefore, the observed 
decrease in Src1 phosphorylation, following the blocking 
of β1-integrin using AIIB2 antibody, appears to involve 
reduced recruitment of Src1 protein to the focal adhesion 
complex, through preventing the interaction with other focal 
adhesion components. Finally, a higher level of Src1 activ-
ity was detected in transfected cells than the untransfected 
control cells and was highest in cells expressing the mutant 
 TFAla253-tGFP protein. This further indicates a possible 
direct interaction between the expressed TF and β1-integrin, 
even in the absence of PAR2 activation.
In conclusion, this study has identified a crucial role for 
Src1 over-activation, in mediating TF signalling, resulting in 
the activation of p38 and subsequent apoptosis in HCAEC. 
In addition, for the first time β1-integrin has been shown to 
act as signalling intermediary associating increased cellu-
lar levels of TF with the over-activation of Src1. Therefore, 
this study has identified a crucial step in the mechanism of 
TF-induced apoptosis. The activation of this pathway deter-
mines the fate of the cells that come into contact with TF, 
and may be crucial during inflammatory conditions such as 
cancer and vascular disease.
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